Stephane de Botton

Aug 23, 2024 | digitalcommons.library.tmc.edu | Jenny Byrne |Stephane de Botton |Pau Montesinos |Andre C Schuh

This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies.

Mar 7, 2024 | touchoncology.com | Florence Pasquier |Stephane de Botton

Leukaemia Read Time: 14 mins Copy Link Published Online: Mar 7th 2024 touchREVIEWS in Oncology & Haematology. 2024;20(1):1–5:Online ahead of journal publication Authors: Florence Pasquier, Stéphane De Botton Quick Links: Overview Management of patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) is challenging, as their prognosis remains poor with conventional therapies, underlining the need for the development of new drugs.